rip3

GSK-843 (GSK'843) is a selective and potent RIP3 inhibitor with an IC50 value of 8.6 nM for the structural domain of RIP3 kinase. It has potential analgesic activity, inhibits the expression of RIP3 and NLRP3 in the SDH of CFA mice, and can be used as adjunctive therapy for treating inflammation.

GSK2593074A (GSK'074) is a programmed necrosis inhibitor that displays inhibitory effects on RIP1 and RIP3.

GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor that binds to the RIP3 kinase domain (IC50: 0.9 nM) and inhibits kinase activity (IC50: 0.3 nM).

GSK583 is a highly effective and specific RIP2 kinase inhibitor (IC50: 5 nM).

HS-1371 is a novel kinase inhibitor of receptor-interacting protein kinase 3 (RIP3) with an IC50 of 20.8 nM.

Necrosulfonamide ((E)-Necrosulfonamide) is a necroptosis inhibitor that targets MLKL and is selective. Necrosulfonamide prevents the MLKL-RIP1-RIP3 necrosomal complex from interacting with its downstream effectors.

RIP3 Activator 1 (compound C8) is an effective RIP3 activator that inhibits cell growth and induces necroptotic cell death (necroptosis) and autophagy through the RIP3/p62/Keap1 signaling pathway. Additionally, this compound enhances the expression of p-MLKL and promotes the accumulation of LC3-II and p62 proteins.

ZBP1/RIP3/MLKL activator 1 (compound 3a) is a synthesized quinoline derivative that can induce DNA damage, elevate intracellular reactive oxygen species (ROS) levels, and trigger apoptosis through the caspase pathway. Furthermore, when apoptosis is inhibited, it facilitates necroptosis via the ZBP1-RIP3-MLKL pathway. This compound is useful in cancer research, particularly for targeting cells with impaired apoptotic mechanisms.

GSK-872 (GSK2399872A) is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity (IC50: 1.8 nM) and inhibits kinase activity (IC50: 1.3 nM).

GSK 872 hydrochloride is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity (IC50: 1.8 nM) and inhibits kinase activity (IC50: 1.3 nM).

Citronellol ((±)-β-Citronellol) is used in insect repellents and perfumes and as a mite attractant.

RIP1-IN-1 is an orally bioavailable RIP1 inhibitor with a high binding affinity (Kd: 110 nM). This compound exhibits significant activity against necroptosis and effectively suppresses necrosome formation by inhibiting the phosphorylation of RIP1, RIP3, and MLKL pathways. RIP1-IN-1 can inhibit necroptosis and is applicable in research on acute liver injury.

RIPK3-IN-2, a RIP3 inhibitor, is utilized in studies of diseases caused by or associated with activated necrotic pathways.

Necrosulfonamide-D4 is the deuterated form of Necrosulfonamide. Necrosulfonamide (T6904) acts as a necroptosis inhibitor by selectively targeting (MLKL). It hinders the interaction between the MLKL-RIP1-RIP3 necrosome complex and its downstream effectors. MLKL serves as a crucial substrate of RIP3 in the necrosis induction process.

Citronellol (Standard) is the standard substance of Citronellol, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Citronellol ((±)-β-Citronellol) is used in insect repellents and perfumes and as a mite attractant.